BLIS Technologies (BLT) H2 2026 earnings summary

Executive summary

• Achieved strong revenue and underlying earnings growth for FY26, driven by disciplined commercial execution and strategic partnerships.

• Resolved a significant intellectual property dispute, securing joint patent ownership and commercial continuity in Europe.

• Advanced regulatory pathway in China with a key clinical trial underway, supporting future growth.

Financial highlights

• FY26 revenue reached $14.7m, up 16% year-over-year from $12.6m.

• Underlying EBITDA was $1.8m after adjusting for a one-off $0.9m supply chain cost; reported EBITDA was $0.9m (FY25: $1.0m).

• Net profit after tax was $0.7m (FY25: $0.8m); underlying NPAT rose 90% to $1.6m.

• Cash and short-term deposits at year-end totaled $8.5m, reflecting inventory investment.

Outlook and guidance

• Entering FY27 with confidence, supported by strengthened partnerships and B2B momentum.

• Priorities include accelerating growth in key markets, supporting China regulatory milestones, advancing R&D, and building brand awareness.

• Minimal economic impact from Middle East conflict anticipated.